MEI Pharma adopts Sixth Amended and Restated Bylaws effective December 18, 2023

Lite Strategy, Inc.

Board designated at eight directors; amendments conform to revised DGCL.
Changes include updated meeting notice rules, adjourned meetings, record date.
Board may now designate any person (not just officers) to chair stockholder meetings.
Director removal standard aligned with DGCL and Certificate of Incorporation.
Administrative updates: gender-neutral terms, waiver by electronic transmission.

Key facts

Extracted from this filing and checked against the source text.

Governance Changes SEC 8-K Item 5.03/5.05/5.06 confidence 0.9

Lite Strategy, Inc.: Amended and restated bylaws to align with DGCL, update meeting procedures, director count, removal standard, and gender-neutral terms (effective 2023-12-18).

Change: bylaw amendment
Effective: 2023-12-18

Exact text from the filing

On December 18, 2023, the Board of Directors (the Board) of MEI Pharma, Inc. (the Company) approved the Sixth Amended and Restated Bylaws of the Company (the Sixth A&R Bylaws), effective immediately.

View on SEC.gov

59 governance changes filed in the last 30 days. Browse all governance changes →

Lite Strategy, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-23-072612

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.